New Treatment Landscape in MS — Preventing Long Term Disability Through High Efficacy Treatments in Early MS

A multidisciplinary panel of experts provide an overview of the progressive nature of multiple sclerosis (MS) and discuss how clinicians, payers, and pharmacists approach management of the disease.

Thomas Leist, MD describes the epidemiology of MS and the journey of patients as the disease progresses.

Experts in MS discuss the evolution in treatment options over time and the shift towards use of early high-efficacy therapy.

Thomas Leist, MD and Darin Okuda, MD provide insight into first-line treatment selection for MS and the patient factors involved.

Maria Lopes, MD, MS discusses payer considerations and challenges in MS treatment management with the ongoing paradigm shift toward early high-efficacy treatment.

Nancy Ross, PharmD, BCACP, MSCS, CSP describes treatment approach and patient navigation in an MS center of excellence.

MS specialist Thomas Leist, MD provides insights into the challenges of evaluating and monitoring patients with MS.

Darin Okuda, MD discusses the risk of undertreating MS patients and the avoidance of undertreatment with newer high-efficacy therapies.

Key opinion leaders in MS describe the impact of generic medication availability on the management of MS and cost of MS treatment.

MS specialists Darin Okuda, MD and Thomas Leist, MD discuss the viability of a generic-first treatment approach in MS.

Thomas Leist, MD and Darin Okuda, MD discuss clinical trials supporting the use of high efficacy MS therapies: ocrelizumab, ofatumumab, and cladribine.

Experts in MS discuss the challenges related to treatment selection and management when MS disease progression occurs.

Thomas Leist, MD and Darin Okuda, MD describe the current landscape of disease guidelines and algorithms in MS treatment.

Key opinion leaders in MS provide closing thoughts on the future of MS treatment including digital therapeutics, new generics, and pipeline drugs on the horizon.